Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy-Reference-Cited by-同舟云学术

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Published:2017-09-08 Issue:20 Volume:1 Page:1729-1738
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Spiegel Jay Y.¹,McNamara Caroline²,Kennedy James A.²,Panzarella Tony³,Arruda Andrea²,Stockley Tracy⁴,Sukhai Mahadeo⁴,Thomas Mariam⁴,Bartoszko Justyna¹,Ho Jenny²,Siddiq Nancy²,Maze Dawn²,Schimmer Aaron²,Schuh Andre²,Sibai Hassan²,Yee Karen²,Claudio Jamie²,Devlin Rebecca²,Minden Mark D.²,Kamel-Reid Suzanne⁴,Gupta Vikas²

Affiliation:

1. Department of Medicine, University of Toronto, Toronto, Canada; and

2. Department of Medical Oncology and Hematology,

3. Department of Biostatistics, and

4. Advanced Molecular Diagnostics Laboratory, University Health Network, Princess Margaret Cancer Centre, Toronto, Canada

Abstract

Key Points ASXL1/EZH2, transfusion dependence, and a high prognostic risk score predict shorter TTF in MF patients on JAK1/2 inhibitors. These clinical and genetic factors were also associated with decreased overall survival.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/20/1729/878744/advances009530.pdf

Reference26 articles.

1. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis;Rumi;Blood,2014

2. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients;Tefferi;Leukemia,2014

3. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients;Guglielmelli;Leukemia,2014

4. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms;Lundberg;Blood,2014

5. Mutations and prognosis in primary myelofibrosis;Vannucchi;Leukemia,2013

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review;Hematology;2024-09-13

2. Advances in Stem Cell Transplantation for Myelofibrosis;Current Hematologic Malignancy Reports;2024-09-06

3. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

4. Myelofibrosis and allogeneic transplantation: critical points and challenges;Frontiers in Oncology;2024-06-20

5. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?;Expert Opinion on Pharmacotherapy;2024-04-12